Dyslipidemia, statins, and venous thromboembolism

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 8, 2011, Pages 897-902

  Poredos, Pavel ^a   Jezovnik, Mateja Kaja ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

coagulation; dyslipidemia; inflammation; statins; Venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ATORVASTATIN; C REACTIVE PROTEIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THROMBIN; WARFARIN;

ARTICLE; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; VENOUS THROMBOEMBOLISM;

DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84555208720     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1297368     Document Type: Article

References (51)

1. Lijfering W M., Flinterman L E., Vandenbroucke J P., Rosend F R., Cannegieter S C. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost 2011 37 8 885-896
2. Jezovnik M K., Poredos P, Stalc M. Impairment of the vasodilatation capability of the brachial artery in patients with idiopathic venous thrombosis. J Atheroscler Thromb 2010 17 11 1190-1198
3. Prandoni P, Bilora F, Marchiori A et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003 348 15 1435-1441 (Pubitemid 36407172)
4. Jezovnik M K., Poredos P, Lusa L. Idiopathic venous thrombosis is associated with preclinical atherosclerosis. J Atheroscler Thromb 2010 17 3 304-311
5. Prandoni P, Ghirarduzzi A, Prins M H. et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 2006 4 9 1891-1896 (Pubitemid 44226764)
6. Ageno W, Dentali F. Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se. Thromb Haemost 2008 100 2 181-183
7. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen P W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008 117 1 93-102 (Pubitemid 350301144)
8. Goldhaber S Z., Savage D D., Garrison R J. et al. Risk factors for pulmonary embolism. The Framingham Study. Am J Med 1983 74 6 1023-1028 (Pubitemid 13101585)
9. Goldhaber S Z., Grodstein F, Stampfer M J. et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997 277 8 642-645 (Pubitemid 27097428)
10. Kawasaki T, Kambayashi J, Ariyoshi H, Sakon M, Suehisa E, Monden M. Hypercholesterolemia as a risk factor for deep-vein thrombosis. Thromb Res 1997 88 1 67-73
11. Nowak-Göttl U, Junker R, Hartmeier M et al. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999 100 7 743-748 (Pubitemid 29383645)
12. Ignatescu M, Kostner K, Zorn G et al. Plasma Lp(a) levels are increased in patients with chronic thromboembolic pulmonary hypertension. Thromb Haemost 1998 80 2 231-232 (Pubitemid 28393614)
13. Lippi G, Brocco G, Manzato F, Guidi G. Relationship between venous thromboembolism and lipid or lipoprotein disorders. Thromb Res 1999 95 6 353-354 (Pubitemid 29486599)
14. von Depka M, Nowak-Göttl U, Eisert R et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000 96 10 3364-3368
15. Lippi G, Bassi A, Brocco G, Manzato F, Marini M, Guidi G. Lipoprotein(a) concentration is not associated with venous thromboembolism in a case control study. Haematologica 1999 84 8 726-729 (Pubitemid 29424409)
16. McColl M D., Sattar N, Ellison J et al. Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism. Blood Coagul Fibrinolysis 2000 11 3 225-229 (Pubitemid 30331800)
17. Ray J G., Rosendaal F R. The role of dyslipidemia and statins in venous thromboembolism. Curr Control Trials Cardiovasc Med 2001 2 4 165-170 (Pubitemid 32780803)
18. Volpato S, Palmieri E, Fellin R, Zuliani G. Acute phase markers are associated with reduced plasma lipid levels in a population of hospitalized elderly patients. Gerontology 2000 46 1 22-27 (Pubitemid 30006792)
19. Sattar N, Petrie J R., Jaap A J. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis 1998 138 2 229-235 (Pubitemid 28313507)
20. Cignarella A, Mussoni L, Mannucci L, Ferioli E, Puglisi L, Tremoli E. Platelet activation supports the development of venous thrombosis in hyperlipidemic rats. Blood Coagul Fibrinolysis 1998 9 1 47-53 (Pubitemid 28144416)
21. Dzeka T N., Derylo B, Arnold JMO. Endothelial function and statins in human veins. Can J Cardiol 2000 16 193F
22. Bladbjerg E M., Marckmann P, Sandström B, Jespersen J. Non-fasting factor VII coagulant activity (FVII:C) increased by high-fat diet. Thromb Haemost 1994 71 6 755-758 (Pubitemid 24177965)
23. Scanu A M. Lipoprotein(a). A genetic risk factor for premature coronary heart disease. JAMA 1992 267 24 3326-3329
24. Lippi G, Franchini M, Guidi G C. Lipoprotein(a), athero-thrombosis and longevity. A historical paradox finally elucidated? Haematologica 2007 92 4 e48
25. Ridker P M., Danielson E, Fonseca F A. et al, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 359 21 2195-2207
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 9326 7-22
27. Undas A, Brummel-Ziedins K E., Mann K G. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005 25 2 287-294 (Pubitemid 40189147)
28. Herrington D M., Vittinghoff E, Lin F et al, HERS Study Group. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002 105 25 2962-2967 (Pubitemid 34693827)
29. Ramcharan A S., Van Stralen K J., Snoep J D., Mantel-Teeuwisse A K., Rosendaal F R., Doggen C J. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 2009 7 4 514-520
30. Sørensen H T., Horvath-Puho E, Søgaard K K. et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009 7 4 521-528
31. Ray J G., Mamdani M, Tsuyuki R T., Anderson D R., Yeo E L., Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001 161 11 1405-1410 (Pubitemid 32681161)
32. Smeeth L, Douglas I, Hall A J., Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009 67 1 99-109
33. Glynn R J., Danielson E, Fonseca F A. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009 360 18 1851-1861
34. Agarwal V, Phung O J., Tongbram V, Bhardwaj A, Coleman C I. Statin use and the prevention of venous thromboembolism: a meta-analysis. Int J Clin Pract 2010 64 10 1375-1383
35. Squizzato A, Galli M, Romualdi E et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J 2010 31 10 1248-1256
36. Lacut K, Le Gal G, Abalain J H., Mottier D, Oger E. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia? Thromb Res 2008 122 3 314-319 (Pubitemid 351888887)
37. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008 121 10, Suppl 1 S21-S31
38. Jezovnik M K., Poredos P. Idiopathic venous thrombosis is related to systemic inflammatory response and to increased levels of circulating markers of endothelial dysfunction. Int Angiol 2010 29 3 226-231
39. Lippi G, Favaloro E J., Montagnana M, Franchini M. C-reactive protein and venous thromboembolism: causal or casual association? Clin Chem Lab Med 2010 48 12 1693-1701
40. Ray K K., Cannon C P. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol 2005 96 5A 54F-60F (Pubitemid 41207734)
41. Albert M A., Danielson E, Rifai N, Ridker P M., PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001 286 1 64-70 (Pubitemid 32606333)
42. Jezovnik M K., Poredos P, Stalc M. Impairment of the vasodilatation capability of the brachial artery in patients with idiopathic venous thrombosis. J Atheroscler Thromb 2010 17 11 1190-1198
43. Spring S, Simon R, van der Loo B et al. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial. Thromb Haemost 2008 99 1 182-189
44. Yang Z, Kozai T, van der Loo B et al. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol 2000 36 5 1691-1697
45. Ali F Y., Armstrong P C., Dhanji A R. et al. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol 2009 29 5 706-711
46. Kröger N, Shimoni A, Zagrivnaja M et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004 104 10 3361-3363 (Pubitemid 39507159)
47. Undas A, Brummel K E., Musial J, Mann K G., Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001 103 18 2248-2253 (Pubitemid 32433713)
48. Cortellaro M, Cofrancesco E, Arbustini E et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost 2002 88 1 41-47 (Pubitemid 34752265)
49. Doggen C J., Lemaitre R N., Smith N L., Heckbert S R., Psaty B M. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2004 2 5 700-701 (Pubitemid 40185706)
50. Keech A, Simes R J., Barter P et al, FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005 366 9500 1849-1861
51. Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med 2010 48 6 749-756